ZVSA

ZyVersa Therapeutics

ZVSA

Market cap $1.52M

Overview Fund Activity

Delisted

ZVSA was delisted on the 16th of July, 2025.

Back to rankings

About: ZyVersa Therapeutics Inc is a clinical-stage biopharmaceutical company leveraging proprietary technologies to develop drugs for patients with chronic renal or inflammatory diseases with high unmet medical needs. The company has two proprietary globally licensed drug development platforms which are Cholesterol Efflux MediatorTM, VAR 200 (2-hydroxypropyl-beta-cyclodextrin) is an injectable drug in clinical development for the treatment of renal diseases. and IC 100 is a monoclonal antibody inflammasome ASC inhibitor in preclinical development for the treatment of inflammatory conditions.

Employees: 7

Healthcare Biotechnology

Financial journalist opinion

ZyVersa Therapeutics Highlights Data Reinforcing the Potential of Inflammasome Inhibitors to Attenuate Progression of Type 2 Diabetes and Improve Associated Long-term Cardiovascular Outcomes

Type 2 diabetes (T2DM), affecting more than 530 million worldwide, is a metabolic disease often coupled with cardiovascular complications including coronary artery disease, heart failure, and stroke. Cardiovascular complications are a leading cause of disability and death in people with T2DM.

ZyVersa Therapeutics Highlights Data Reinforcing the Potential of Inflammasome Inhibitors to Attenuate Progression of Type 2 Diabetes and Improve Associated Long-term Cardiovascular Outcomes

ZyVersa Therapeutics Highlights Lipidomic Data in Alport Syndrome and DKD Reinforcing the Need for Drugs to Attenuate Damaging Renal Lipid Accumulation to Mitigate Disease Progression

Lipid alterations in Alport syndrome are linked to impaired ABCA1 lipid efflux and the underlying renal injury processes of lipotoxicity and inflammation.

ZyVersa Therapeutics Highlights Lipidomic Data in Alport Syndrome and DKD Reinforcing the Need for Drugs to Attenuate Damaging Renal Lipid Accumulation to Mitigate Disease Progression

ZyVersa Therapeutics Highlights Data Demonstrating a Critical Need for Therapies to Address Kidney Lipotoxicity to Alleviate Diabetic Kidney Disease (DKD) and Its Progression

Lipid accumulation in the kidneys' filtration system results in inflammation and fibrosis that cause progressive kidney damage and disease progression.

ZyVersa Therapeutics Highlights Data Demonstrating a Critical Need for Therapies to Address Kidney Lipotoxicity to Alleviate Diabetic Kidney Disease (DKD) and Its Progression

ZyVersa Therapeutics Reports Second Quarter 2025 Financial Results and Highlights Key Near-term Value-building Milestones

KEY HIGHLIGHTS First clinical site for Phase 2a clinical trial for Cholesterol Efflux Mediator™ VAR 200 in patients with diabetic kidney disease (DKD) was activated June 2025; patient screening is underway, with interim results expected ~Q4-2025. IND-enabling obesity preclinical study with Inflammasome ASC Inhibitor IC 100 in a diet-induced obesity (DIO) animal model planned to begin ~Q4-2025.

ZyVersa Therapeutics Reports Second Quarter 2025 Financial Results and Highlights Key Near-term Value-building Milestones

ZyVersa Therapeutics CEO Issues Mid-year Shareholder Letter Highlighting Recent Corporate Developments and R&D Progress

WESTON, Fla., July 21, 2025 (GLOBE NEWSWIRE) -- ZyVersa Therapeutics, Inc. (Nasdaq: ZVSA; “ZyVersa”), a clinical stage specialty biopharmaceutical company developing first-in-class drugs for treatment of patients with renal and inflammatory diseases who have unmet medical needs, announces that Stephen C. Glover, Co-Founder, Chairman, Chief Executive Officer, and President, has issued a mid-year Shareholder Letter to update investors on recent corporate developments and to highlight near-term value-building R&D milestones for second half of 2025. The full text of the letter follows.

ZyVersa Therapeutics CEO Issues Mid-year Shareholder Letter Highlighting Recent Corporate Developments and R&D Progress

Why Did ZyVersa Therapeutics Stock Shoot Higher On Tuesday?

ZyVersa Therapeutics, Inc. ZVSA stock was trading higher on Tuesday, with a session volume of 160.9 million compared to the average volume of 4.03 million as per data from Benzinga Pro.

Why Did ZyVersa Therapeutics Stock Shoot Higher On Tuesday?

ZyVersa Therapeutics Announces a Warrant Inducement Transaction for $2.0 Million in Gross Proceeds

WESTON, Fla., July 08, 2025 (GLOBE NEWSWIRE) -- ZyVersa Therapeutics, Inc. (Nasdaq: ZVSA; “ZyVersa”), a clinical stage specialty biopharmaceutical company developing first-in-class drugs for treatment of patients with renal and inflammatory diseases who have unmet medical needs, today announced its entry into a warrant inducement agreement with a single institutional investor of the Company. Terms of the warrant inducement agreement include the immediate exercise of Series A-2 Warrants to purchase up to 957,200 shares of common stock (the “Series A-2 Warrants”) and Series A-3 Warrants to purchase up to 2,105,265 shares of common stock (the “Series A-3 Warrants,” and together with the Series A-2 Warrants, the “Existing Warrants”) at a reduced exercise price of $0.67. Gross cash proceeds were approximately $2.0 million before deducting financial advisor fees and other transaction expenses. The Company intends to use the net proceeds from the offering for working capital and other general corporate purposes.

ZyVersa Therapeutics Announces a Warrant Inducement Transaction for $2.0 Million in Gross Proceeds

ZyVersa Therapeutics Supports FDA-Authorized Emergency Compassionate Use of Cholesterol Efflux Mediator™ VAR 200 in a Patient with ApoCII Amyloidosis

ApoCII amyloidosis, resulting from abnormal organ deposition of toxic fibrillar amyloid proteins, is an ultra-rare condition that mostly affects the kidneys and manifests with protein spillage into the urine (proteinuria) and chronic kidney disease. Despite being treated with standard-of-care renal drug therapy (ACEi, SGLT2, statin, and ezetimibe), the patient authorized by FDA to receive VAR 200 is showing continued kidney disease progression.

ZyVersa Therapeutics Supports FDA-Authorized Emergency Compassionate Use of Cholesterol Efflux Mediator™ VAR 200 in a Patient with ApoCII Amyloidosis

ZyVersa Therapeutics Announces First Clinical Site Activation, Initiating Patient Recruitment for Cholesterol Efflux Mediator™ VAR 200's Phase 2a Clinical Trial in Patients with Diabetic Kidney Disease (DKD)

Site initiation for Phase 2a DKD trial marks a key milestone for ZyVersa, and for development of VAR 200, a first-in-class treatment for kidney disease.

ZyVersa Therapeutics Announces First Clinical Site Activation, Initiating Patient Recruitment for Cholesterol Efflux Mediator™ VAR 200's Phase 2a Clinical Trial in Patients with Diabetic Kidney Disease (DKD)

ZyVersa Therapeutics Announces Share Purchase Agreement for up to $10 Million in Partnership with Williamsburg Venture Holdings to Fund Clinical Development of Cholesterol Efflux Mediator™ VAR 200

WESTON, Fla., June 25, 2025 (GLOBE NEWSWIRE) -- ZyVersa Therapeutics, Inc. (Nasdaq: ZVSA; “ZyVersa”), a clinical stage specialty biopharmaceutical company developing first-in-class drugs for treatment of patients with renal and inflammatory diseases who have unmet medical needs, announces that it has entered into a share purchase agreement (SPA) with Williamsburg Venture Holdings (WVH), an institutional investor. We anticipate that this partnership will provide a flexible source of funding, enabling the company to progress clinical development of Cholesterol Efflux Mediator™ VAR 200 to treat chronic kidney diseases. The global drug market for kidney diseases was $18 Billion in 2024, with $30 Billion projected by 2034 (Precedence Research).

ZyVersa Therapeutics Announces Share Purchase Agreement for up to $10 Million in Partnership with Williamsburg Venture Holdings to Fund Clinical Development of Cholesterol Efflux Mediator™ VAR 200

See News Rankings

Charts implemented using Lightweight Charts™